EPS Creative Health sets HK$60.25 million share settlement for R&E acquisition vendor, closing due by July 2026

• EPS Creative Health Technology Group is updating its acquisition of a 65% stake in R&E Corporation, with the earnout lifting consideration.
• Audit Certificate showed Actual Profit of HK$57.94 million, above the target, raising the Promissory Note outstanding sum to HK$60.25 million.
• The vendor is set to receive 60,252,419 consideration shares at HK$1 each to offset the full outstanding sum.
• Subscription completion is expected on or before July 31, 2026; the shares would represent about 10.35% of enlarged share capital.
• EPS Holdings’ stake would fall to 64.38% from 71.81% on issuance; total shares would rise to 582,429,838 from 522,177,419.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EPS Creative Health Technology Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245345), on July 15, 2026, and is solely responsible for the information contained therein.